Investment Summary

Eight Roads Invests In Toppr

On May 1, 2015, private equity firm Eight Roads invested in internet software and services company Toppr

Investment Highlights
  • This is Eight Roads’ 24th transaction in the Internet Software and Services sector.
  • This is Eight Roads’ 15th transaction in India.

Investment Summary
Date 2015-05-01
Target Toppr
Sector Internet Software and Services
Investor(s) Eight Roads
Deal Type Venture

Target

Toppr

Mumbai, India
Toppr is an online test preparation platform. Toppr is based in Mumbai, Maharashtra.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Eight Roads

Investor

Category Private Equity Firm
Founded 1969
Size Small
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 104 of 298
Sector (Internet Software and Services) 24 of 60
Type (Venture) 86 of 269
Country (India) 15 of 38
Year (2015) 16 of 26
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-29 Blueprint Medicines

Cambridge, Massachusetts, United States

Blueprint Medicines is a bio pharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Blueprint Medicines was founded in 2008 and is based in Cambridge, Massachusetts.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-06 Adaptimmune

Abingdon, United Kingdom

Adaptimmune is a clinical-stage biopharmaceutical company, that focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. Adaptimmune was founded in 2008 and is based in Abingdon, England.

Sell -
Mergr

Product

Company

Legal